Your Article Summary
See Latest ArticlesDynamics and management of cytopenias associated with dasatinib therapy in patients with chronic myeloid leukemia in chronic phase after imatinib failure
Cancer, 06/15/09
Quintás-Cardama A et al. – Study reports that hematologic toxicity was frequent during dasatinib therapy in patients with chronic myeloid leukemia in chronic phase (CP CML), particularly at doses >100 mg daily. Treatment interruption and/or dose reduction as well as growth factor support were safe and efficacious strategies to facilitate the continuous administration of dasatinib.
Methods- Aim was to investigate the incidence, dynamics, and management of cytopenias in ps with CP CML who received dasatinib therapy after imatinib failure
- Data were analyzed from 130 pts in phase 1 (n=22) or phase 2 or 3 (n=108) studies for grade 2 to 4 cytopenia
- Grade 2 to 4 neutropenia and/or thrombocytopenia occurred in 94 (72%) pts during dasatinib therapy
- Grade 3 to 4 occurred in 67 (52%) pts
- Of the 94 pts who developed grade 2 to 4 neutropenia and/or thrombocytopenia-
- 68% also developed at least grade 2 anemia, and
- 17% grade 3 to 4 anemia
- Management of cytopenias included:
- Transient dasatinib interruption in 35 (37%) pts
- Filgrastim in 12 (14%) pts
- Recombinant erythropoietin in 29 (45%) pts, and
- Interleukin-11 in 3 (5%) pts
- Factors associated with an increased risk for developing grade 2 to 4 cytopenias were:
- Longer time from diagnosis to treatment
- Prior interferon or imatinib therapy, and
- Lower white blood cell count at the initiation of dasatinib therapy
- 68% also developed at least grade 2 anemia, and
Related Articles
Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response, a study of the GIMEMA CML WP
Blood, 10/09/09
Relevance Score: 82%
Epidemiological study on survival of chronic myeloid leukemia (CML) and Ph+ acute lymphoblastic leukemia (ALL) patients with BCR-ABL T315I mutation
Blood, 11/06/09
Relevance Score: 81%
SUZ12 is a candidate target of the non-canonical WNT pathway in the progression of chronic myeloid leukemia
Genes, Chromosomes and Cancer, 10/28/09
Relevance Score: 81%
Novartis drug Tasigna meets primary endpoint in pivotal trial against Glivec as first-line treatment in chronic myeloid leukemia patients
Novartis, 10/21/09
Relevance Score: 81%
Dasatinib treatment of chronic phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations
Blood, 10/02/09
Relevance Score: 81%
Today in Leukemia/Lymphoma...keeping you current
Receive free subspecialty "5-minute updates" via email
Salvage treatment for children with refractory first or second relapse of acute myeloid leukaemia with gemtuzumab ozogamicin: results of a phase II study
British Journal of Haematology, 12/11/09
Advances in the understanding and management of angioimmunoblastic T-cell lymphoma
British Journal of Haematology, 12/11/09
Efficacy and safety of intravenous voriconazole and intravenous itraconazole for antifungal prophylaxis in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome
Supportive Care in Cancer, 12/11/09
Today in Pharmacology/Therapy...keeping you current
Receive free subspecialty "5-minute updates" via email
Clinical Benefit of Allogeneic Melanoma Cell Lysate–Pulsed Autologous Dendritic Cell Vaccine in MAGE-Positive Colorectal Cancer Patients
Clinical Cancer Research, 12/11/09
Radiation Therapy for Rectal Cancer: Current Status and Future Directions
Cancer Control, 12/11/09
Current Progress in Targeted Therapy for Colorectal Cancer
Cancer Control, 12/11/09
Today in Side Effects...keeping you current
Receive free subspecialty "5-minute updates" via email
Unanticipated toxicities from anticancer therapies: Survivors perspectives
Supportive Care in Cancer, 12/11/09
Efficacy of venlafaxine, medroxyprogesterone acetate, and cyproterone acetate for the treatment of vasomotor hot flushes in men taking gonadotropin-releasing hormone analogues for prostate cancer: A double-blind, randomised trial
The Lancet Oncology - Online First, 12/09/09
Effects of functional electrical stimulation on dysphagia caused by radiation therapy in patients with nasopharyngeal carcinoma
Supportive Care in Cancer, 12/09/09